Evidence map›Paper›PMID 29222698›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2018

Efficacy evaluation of iclaprim in a neutropenic rat lung infection model with methicillin-resistant Staphylococcus aureus entrapped in alginate microspheres.

David B Huang, Ian Morrissey, Timothy Murphy, Stephen Hawser, Mark H Wilcox

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. The Application of Rat Models inPathogens (Basel, Switzerland) · 2024
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

David B HuangMotif BioSciences, 125th Park Avenue, 25th Floor, New York, NY, 10017, USA. david.huang@motifbio.com.
Ian MorrisseyIHMA Europe Sàrl, Route de I'Ile-au-Bois 1A, 1870, Monthey, VS, Switzerland.
Timothy MurphyNeoSome Life Sciences, LLC, Lexington, MA, USA.
Stephen HawserIHMA Europe Sàrl, Route de I'Ile-au-Bois 1A, 1870, Monthey, VS, Switzerland.
Mark H WilcoxLeeds Teaching Hospitals & University of Leeds, Leeds, UK.
Motif BioSciences (United States) · USUniversity of Leeds · GBWave Life Sciences (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study was to demonstrate the efficacy of iclaprim in a neutropenic rat lung infection model with methicillin-resistant Staphylococcus aureus (MRSA) entrapped in alginate beads. An inoculum of 5.25 × 10

Indexed as

AlginatesAnimalsAnti-Bacterial AgentsDisease Models, AnimalDrug CarriersGlucuronic AcidHexuronic AcidsMaleMethicillin-Resistant Staphylococcus aureusMicrospheresPneumonia, StaphylococcalPyrimidinesRatsRats, Sprague-DawleyTreatment OutcomeAlginatesAnti-Bacterial AgentsDrug CarriersGlucuronic AcidHexuronic AcidsiclaprimPyrimidines

Identifiers

PMID29222698
OpenAlexW2771774243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.